Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Key Inclusion Criteria:

• Documented diagnosis of B-cell CLL, with diagnosis established according toInternational Workshop on Chronic Lymphocytic Leukemia (IWCLL)

• No prior therapy for CLL other than corticosteroids for disease complications

• CLL that warrants treatment

• Presence of measurable lymphadenopathy

• Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2

Key Exclusion Criteria:

• Known histological transformation from CLL to an aggressive lymphoma (ie, Richtertransformation)

• Known presence of myelodysplastic syndrome

• Evidence of ongoing systemic bacterial, fungal, or viral infection at the time ofrandomization

• Ongoing liver injury

• History of non-infectious pneumonitis

• Ongoing inflammatory bowel disease

• History of prior allogeneic bone marrow progenitor cell or solid organ transplantation

• Ongoing immunosuppressive therapy other than corticosteroids

• Received last dose of study drug on another therapeutic clinical trial within 30 daysprior to randomization Note: Other protocol defined Inclusion/Exclusion criteria may apply.